CRSP
CRISPR Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.20 / 10
Outperform
Sentiment is outperforms (6.2) and fund‑flow score 8.0 (excellent), with strong overall and block inflows but negative small/medium/large patterns. Analyst consensus is 100% Buy from one firm, historical win rate 50% and weighted rating 4.39. Overall bullish bias.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-17
InstitutionPiper Sandler
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for CRSP?
- CRSP holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.20/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
